Committed to harnessing the power and potential of genome editing to develop transformative medicines for patients suffering from serious diseases

Editas Medicine (NASDAQ: EDIT) is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The Company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.

Year Invested: 2013
Location: Cambridge, Mass.

Recent News

February 28, 2019
Editas Medicine Supports Global Movement to Raise Awareness on Rare Disease Day®

February 28, 2019
Editas Medicine Announces Fourth Quarter and Full Year 2018 Results and Update

February 21, 2019
Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2018 Corporate Update and Results

Read More News

Associated Team Members

Alexis Borisy